z-logo
Premium
Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors
Author(s) -
Schachtner Thomas,
Stein Maik,
Reinke Petra
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12695
Subject(s) - medicine , sepsis , transplantation , immunosuppression , immunology , diabetes mellitus , lymphocyte , endocrinology
Background As immunosuppressive therapy and allograft survival have improved, the increased incidence of sepsis has become a major hurdle of disease‐free survival after renal transplantation. Methods We identified 112 of 957 kidney transplant recipients ( KTR s) with sepsis. In all, 31 KTR s developed severe sepsis or septic shock, and 30 KTR s died from sepsis. KTR s without sepsis were used for comparison. CMV ‐specific and alloreactive T cells were measured using an interferon‐γ Elispot assay. The extent of immunosuppression was quantified by lymphocyte subpopulations. Results Five‐year patient survival was 70.3% with sepsis compared to 88.2% without ( P <.001). Five‐year estimated glomerular filtration rate was lower in KTR s developing sepsis ( P <.001). Upon multivariate analysis, diabetes, lymphocyte‐depleting induction, donor age, CMV replication, and acute rejection increased the risk of sepsis ( P <.05). Age, diabetes, underweight/obesity, and pneumonia as site of infection were predictive factors of mortality ( P <.05). Early‐onset sepsis was associated with decreased CD 3+ and CD 4+ T cells pre‐transplantation ( P <.05). Impaired CMV ‐specific cellular immunity pre‐transplantation was associated with CMV replication and early‐onset sepsis ( P <.05). High frequencies of alloreactive T cells were associated with acute rejection, lymphocyte‐depleting rejection treatment, and early‐onset sepsis ( P <.05). Conclusion KTR s developing sepsis show inferior patient survival and allograft function. Identified risk factors and differences in lymphocyte counts, CMV ‐specific immunity, and alloreactivity may prove useful to identify KTR s at increased risk.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom